Dina Shlyakter
Overview
Explore the profile of Dina Shlyakter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
47
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farmer L, Ledeboer M, Hoock T, Arnost M, Bethiel R, Bennani Y, et al.
J Med Chem
. 2015 Aug;
58(18):7195-216.
PMID: 26230873
While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential...
2.
Wang T, Duffy J, Wang J, Halas S, Salituro F, Pierce A, et al.
J Med Chem
. 2009 Dec;
52(24):7938-41.
PMID: 20014869
The synthesis and characterization of a novel polycyclic azaindole based derivative is disclosed, and its binding to JAK2 is described. The compound is further evaluated for its ability to block...
3.
Wang T, Ledeboer M, Duffy J, Salituro F, Pierce A, Zuccola H, et al.
Bioorg Med Chem Lett
. 2009 Dec;
20(1):153-6.
PMID: 19945871
Pictet-Spengler condensation of aldehydes or alpha-keto-esters with 4-(2-anilinophenyl)-7-azaindole (11) or deazapurine (12) gave high yields of the 3,4-fused cyclic compounds. SAR studies, by varying the substituted benzaldehyde components, lead to...
4.
Ledeboer M, Pierce A, Duffy J, Gao H, Messersmith D, Salituro F, et al.
Bioorg Med Chem Lett
. 2009 Oct;
19(23):6529-33.
PMID: 19857967
Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis. In an effort to uncover therapeutic...